These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21177179)

  • 21. Current status of drug therapy for inflammatory bowel disease.
    Peppercorn MA
    Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
    Andreoli A; Spinella S; Levenstein S; Prantera C
    Ital J Gastroenterol; 1994 Apr; 26(3):121-5. PubMed ID: 7914759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulfasalazine-induced exacerbation of ulcerative colitis.
    Schwartz AG; Targan SR; Saxon A; Weinstein WM
    N Engl J Med; 1982 Feb; 306(7):409-12. PubMed ID: 6120459
    [No Abstract]   [Full Text] [Related]  

  • 26. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.
    Kruis W; Judmaier G; Kayasseh L; Stolte M; Theuer D; Scheurlen C; Hentschel E; Kratochvil P
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):391-6. PubMed ID: 7614099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
    Jo Y; Matsumoto T; Iida M
    Nihon Rinsho; 2005 May; 63(5):820-4. PubMed ID: 15881176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis.
    Dichi I; Frenhane P; Dichi JB; Correa CR; Angeleli AY; Bicudo MH; Rodrigues MA; Victória CR; Burini RC
    Nutrition; 2000 Feb; 16(2):87-90. PubMed ID: 10696629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis.
    Thomas GA; Rhodes J; Ragunath K; Mani V; Williams GT; Newcombe RG; Russell MA; Feyerabend C
    Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):769-76. PubMed ID: 8864674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
    Sinha A; Nightingale J; West KP; Berlanga-Acosta J; Playford RJ
    N Engl J Med; 2003 Jul; 349(4):350-7. PubMed ID: 12878742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative efficacy of mezakol and sulfasalazine in treating chronic relapsing ulcerative colitis].
    Rogozina VA; Rumiantsev VG
    Eksp Klin Gastroenterol; 2003; (1):58-9, 183. PubMed ID: 12664788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Observation on clinical effect of ZHUANG medicine mediated thread moxibustion combined with medication for patients with ulcerative colitis].
    Zhang LC; Zhang S; Zhong W; Long JX; Li XN; Chen LS
    Zhen Ci Yan Jiu; 2013 Oct; 38(5):399-402. PubMed ID: 24308188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is continuous sulfasalazine necessary in the management of patients with ulcerative colitis? Results of a preliminary study.
    Dickinson RJ; King A; Wight DG; Hunter JO; Neale G
    Dis Colon Rectum; 1985 Dec; 28(12):929-30. PubMed ID: 2866071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.
    Palmer KR; Goepel JR; Holdsworth CD
    Br Med J (Clin Res Ed); 1981 May; 282(6276):1571-3. PubMed ID: 6113021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulphasalazine rectal enemas: topical method of inducing remission of active ulcerative colitis affecting rectum and descending colon.
    Serebro H; Kay S; Javett S; Abrahams C
    Br Med J; 1977 Nov; 2(6097):1264. PubMed ID: 22378
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of sulfasalazine on biopsy mucosal pathologies and histological grading of patients with active ulcerative colitis.
    Zhong YQ; Huang HR; Zhu ZH; Chen QK; Zhan J; Xing LC
    World J Gastroenterol; 2005 Jul; 11(28):4435-8. PubMed ID: 16038049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Enterosorption in the treatment of ulcerative colitis patients].
    Bereza NM; Selezneva SI; Mosalova NM; Boĭko TI; Cherniakova VI; Shevtsova ZI; Kudriavtseva VE
    Lik Sprava; 1992 Jan; (1):97-100. PubMed ID: 1364626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.